FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988130071> ?p ?o ?g. }

• W1988130071 endingPage "258" @default.
• W1988130071 startingPage "253" @default.
• W1988130071 abstract "We have shown previously that conjugation of polyethylene glycol (PEG) chains to recombinant human acetylcholinesterase (rHuAChE) results in the extension of its residence time in the circulation of mice and monkeys [1], [2]. By profiling the pharmacokinetic behavior of an array of well-defined hypolysine human mutant AChE molecules following PEGylation, we now determine that the duration of these enzyme forms in the circulation of rhesus macaques correlates with their number of appended PEG moieties, and is influenced by the actual location of the PEG chains at the molecule surface, as well. These findings, which concur with those we have previously established in mice, indicate that a common set of rules dictates the circulatory fate of PEGylated HuAChEs in rodents and non-human primates. In addition to its effect on circulatory residence, PEGylation reduces the ability of the rHuAChE bioscavenger to elicit an immune response in the heterologous mouse animal system. Thus, an inverse relationship between anti-AChE antibody production and PEG loading was observed following repeated administration of the different PEGylated hypolysine human AChEs to mice. We note however, that in rhesus macaques, the essentially homologous (human) AChE does not induce specific anti-AChE antibodies after repeated administration of high doses of the enzyme in its PEGylated form, and even in its non-PEGylated form. Taken together, these findings indicate that PEG acts by veiling enzyme-related epitopes, which would otherwise interact with host circulatory elimination pathways and immune system. The barring of such interactions by obstructive PEGs, confers the enzyme molecule with both extended circulatory residence and mitigated immunogenic properties. Further modulation by incorporation of the F338A mutation into the PEGylated hypolysine rHuAChE enzyme mold, resulted in the generation of an OP-bioscavenger that displayed reduced aging rates and could effectively protect mice against repeated exposure to CW agents. This selected 4-PEG F338A-AChE can serve as a paradigm for new generation OP-bioscavengers, specifically tailored for prophylactic treatment against toxic OP-agents." @default.
• W1988130071 created "2016-06-24" @default.
• W1988130071 creator A5015533648 @default.
• W1988130071 creator A5024386954 @default.
• W1988130071 creator A5046109966 @default.
• W1988130071 creator A5050309650 @default.
• W1988130071 creator A5083800335 @default.
• W1988130071 creator A5085899754 @default.
• W1988130071 creator A5087981310 @default.
• W1988130071 date "2010-09-01" @default.
• W1988130071 modified "2023-09-30" @default.
• W1988130071 title "Next generation OP-bioscavengers: A circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics" @default.
• W1988130071 cites W1480316552 @default.
• W1988130071 cites W1679034178 @default.
• W1988130071 cites W1777082036 @default.
• W1988130071 cites W1778515962 @default.
• W1988130071 cites W1912267978 @default.
• W1988130071 cites W1969489179 @default.
• W1988130071 cites W1979572414 @default.
• W1988130071 cites W1997080747 @default.
• W1988130071 cites W2011091423 @default.
• W1988130071 cites W2017248525 @default.
• W1988130071 cites W2040103562 @default.
• W1988130071 cites W2058577661 @default.
• W1988130071 cites W2058621211 @default.
• W1988130071 cites W2061830848 @default.
• W1988130071 cites W2077732265 @default.
• W1988130071 cites W2079963068 @default.
• W1988130071 cites W2083461705 @default.
• W1988130071 cites W2091362012 @default.
• W1988130071 cites W2091805300 @default.
• W1988130071 cites W2134158304 @default.
• W1988130071 cites W2239381571 @default.
• W1988130071 cites W4237639166 @default.
• W1988130071 cites W4250406652 @default.
• W1988130071 doi "https://doi.org/10.1016/j.cbi.2009.12.004" @default.
• W1988130071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20005217" @default.
• W1988130071 hasPublicationYear "2010" @default.
• W1988130071 type Work @default.
• W1988130071 sameAs 1988130071 @default.
• W1988130071 citedByCount "8" @default.
• W1988130071 countsByYear W19881300712012 @default.
• W1988130071 countsByYear W19881300712013 @default.
• W1988130071 countsByYear W19881300712014 @default.
• W1988130071 countsByYear W19881300712020 @default.
• W1988130071 crossrefType "journal-article" @default.
• W1988130071 hasAuthorship W1988130071A5015533648 @default.
• W1988130071 hasAuthorship W1988130071A5024386954 @default.
• W1988130071 hasAuthorship W1988130071A5046109966 @default.
• W1988130071 hasAuthorship W1988130071A5050309650 @default.
• W1988130071 hasAuthorship W1988130071A5083800335 @default.
• W1988130071 hasAuthorship W1988130071A5085899754 @default.
• W1988130071 hasAuthorship W1988130071A5087981310 @default.
• W1988130071 hasConcept C10138342 @default.
• W1988130071 hasConcept C104317684 @default.
• W1988130071 hasConcept C112705442 @default.
• W1988130071 hasConcept C143065580 @default.
• W1988130071 hasConcept C159654299 @default.
• W1988130071 hasConcept C162324750 @default.
• W1988130071 hasConcept C181199279 @default.
• W1988130071 hasConcept C185592680 @default.
• W1988130071 hasConcept C203014093 @default.
• W1988130071 hasConcept C2776964284 @default.
• W1988130071 hasConcept C2778816929 @default.
• W1988130071 hasConcept C2779149719 @default.
• W1988130071 hasConcept C54400483 @default.
• W1988130071 hasConcept C55493867 @default.
• W1988130071 hasConcept C86803240 @default.
• W1988130071 hasConcept C8891405 @default.
• W1988130071 hasConcept C98274493 @default.
• W1988130071 hasConceptScore W1988130071C10138342 @default.
• W1988130071 hasConceptScore W1988130071C104317684 @default.
• W1988130071 hasConceptScore W1988130071C112705442 @default.
• W1988130071 hasConceptScore W1988130071C143065580 @default.
• W1988130071 hasConceptScore W1988130071C159654299 @default.
• W1988130071 hasConceptScore W1988130071C162324750 @default.
• W1988130071 hasConceptScore W1988130071C181199279 @default.
• W1988130071 hasConceptScore W1988130071C185592680 @default.
• W1988130071 hasConceptScore W1988130071C203014093 @default.
• W1988130071 hasConceptScore W1988130071C2776964284 @default.
• W1988130071 hasConceptScore W1988130071C2778816929 @default.
• W1988130071 hasConceptScore W1988130071C2779149719 @default.
• W1988130071 hasConceptScore W1988130071C54400483 @default.
• W1988130071 hasConceptScore W1988130071C55493867 @default.
• W1988130071 hasConceptScore W1988130071C86803240 @default.
• W1988130071 hasConceptScore W1988130071C8891405 @default.
• W1988130071 hasConceptScore W1988130071C98274493 @default.
• W1988130071 hasIssue "1-3" @default.
• W1988130071 hasLocation W19881300711 @default.
• W1988130071 hasLocation W19881300712 @default.
• W1988130071 hasOpenAccess W1988130071 @default.
• W1988130071 hasPrimaryLocation W19881300711 @default.
• W1988130071 hasRelatedWork W1985769331 @default.
• W1988130071 hasRelatedWork W2009938139 @default.
• W1988130071 hasRelatedWork W2014540396 @default.
• W1988130071 hasRelatedWork W2246230450 @default.
• W1988130071 hasRelatedWork W2480132860 @default.
• W1988130071 hasRelatedWork W2606684918 @default.

• next